These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 30646339)

  • 1. Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.
    Kennedy RE; Cutter GR; Fowler ME; Schneider LS
    JAMA Netw Open; 2018 Nov; 1(7):e184080. PubMed ID: 30646339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memantine for dementia.
    McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.
    Lopez OL; Becker JT; Wahed AS; Saxton J; Sweet RA; Wolk DA; Klunk W; Dekosky ST
    J Neurol Neurosurg Psychiatry; 2009 Jun; 80(6):600-7. PubMed ID: 19204022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative.
    Schneider LS; Insel PS; Weiner MW;
    Arch Neurol; 2011 Jan; 68(1):58-66. PubMed ID: 21220675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.
    Huisa BN; Thomas RG; Jin S; Oltersdorf T; Taylor C; Feldman HH
    J Alzheimers Dis; 2019; 67(2):707-713. PubMed ID: 30636733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.
    Dysken MW; Sano M; Asthana S; Vertrees JE; Pallaki M; Llorente M; Love S; Schellenberg GD; McCarten JR; Malphurs J; Prieto S; Chen P; Loreck DJ; Trapp G; Bakshi RS; Mintzer JE; Heidebrink JL; Vidal-Cardona A; Arroyo LM; Cruz AR; Zachariah S; Kowall NW; Chopra MP; Craft S; Thielke S; Turvey CL; Woodman C; Monnell KA; Gordon K; Tomaska J; Segal Y; Peduzzi PN; Guarino PD
    JAMA; 2014 Jan; 311(1):33-44. PubMed ID: 24381967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing.
    Blaszczyk AT; Mang BH; Garza H; Mathys M
    Consult Pharm; 2018 May; 33(5):273-282. PubMed ID: 29789049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis.
    Kishi T; Matsunaga S; Oya K; Nomura I; Ikuta T; Iwata N
    J Alzheimers Dis; 2017; 60(2):401-425. PubMed ID: 28922160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease.
    Schmidt R; Hofer E; Bouwman FH; Buerger K; Cordonnier C; Fladby T; Galimberti D; Georges J; Heneka MT; Hort J; Laczó J; Molinuevo JL; O'Brien JT; Religa D; Scheltens P; Schott JM; Sorbi S
    Eur J Neurol; 2015 Jun; 22(6):889-98. PubMed ID: 25808982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors.
    Grossberg GT; Alva G; Hendrix S; Ellison N; Kane MC; Edwards J
    Alzheimer Dis Assoc Disord; 2018; 32(3):173-178. PubMed ID: 29771687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
    Schneider LS; Dagerman KS; Higgins JP; McShane R
    Arch Neurol; 2011 Aug; 68(8):991-8. PubMed ID: 21482915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Régie de l'Assurance Maladie du Québec database.
    Lachaine J; Beauchemin C; Crochard A; Bineau S
    Can J Psychiatry; 2013 Apr; 58(4):195-200. PubMed ID: 23547642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Alzheimer's disease in the long-term-care setting.
    Smith DA
    Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
    Wattmo C; Wallin ÅK
    Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal medication usage in Alzheimer disease patients.
    Zhu CW; Livote EE; Kahle-Wrobleski K; Scarmeas N; Albert M; Brandt J; Blacker D; Sano M; Stern Y
    Alzheimer Dis Assoc Disord; 2010; 24(4):354-9. PubMed ID: 20625271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.
    Kim DH; Brown RT; Ding EL; Kiel DP; Berry SD
    J Am Geriatr Soc; 2011 Jun; 59(6):1019-31. PubMed ID: 21649634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.